HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

4-sulfoxyphenylacetyl dehydroalanine (AD 19)

Also Known As:
AD 19; AD-19; parasulfoxyphenyl-acetyl dehydroalanine
Networked: 22 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Bi, Ni: 1 article (01/2022)
2. Ham, Lillian: 1 article (01/2022)
3. Kreisl, William C: 1 article (01/2022)
4. Li, Tao: 1 article (01/2022)
5. McGwier, Meghan: 1 article (01/2022)
6. Page, Emily: 1 article (01/2022)
7. Segalà, Laura: 1 article (01/2022)
8. Shi, ZhiYue: 1 article (01/2022)
9. Snow, Joseph: 1 article (01/2022)
10. Summers, Angela C: 1 article (01/2022)

Related Diseases

1. Alzheimer Disease (Alzheimer's Disease)
2. Cognitive Dysfunction
01/01/2012 - "Thirty-six patients with AD, 19 patients with amnestic mild cognitive impairment (aMCI), and 23 cognitively normal (CN) subjects were recruited. "
01/01/2022 - "Method: Seventy-three older adults (13 healthy controls, 25 mild cognitive impairment [MCI], 16 mild AD, 19 moderate AD) were evaluated with a neuropsychological battery including the MSVT and activities of daily living (ADL) measures. "
01/01/2000 - "A sample of 44 patients with probable Alzheimer's disease (AD), 19 with possible AD, 39 patients with cognitive impairment without dementia and 14 control subjects were evaluated. "
11/01/2016 - "To determine serum activities of angiotensin-converting enzyme (ACE) as a marker in diagnosis and determine the severity of Alzheimer's disease (AD), METHODS: We measured serum ACE activities in 59 moderate-severe AD, 19 mild AD, 45 amnestic mild cognitive impairment (aMCI) and 39 controls. "
04/18/2023 - "We have examined the relationship between CSF ANGPT2 and CSF markers of BBB leakiness and disease pathology, across three independent cohorts: (i) 31 AD patients and 33 healthy controls grouped according to their biomarker profile (i.e., AD cases t-tau > 400 pg/mL, p-tau > 60 pg/mL and Aβ42 < 550 pg/mL); (ii) 121 participants in the Wisconsin Registry for Alzheimer's Prevention or Wisconsin Alzheimer's Disease Research study (84 participants cognitively unimpaired (CU) enriched for a parental history of AD, 19 participants with mild cognitive impairment (MCI), and 21 with AD); (iii) a neurologically normal cohort aged 23-78 years with paired CSF and serum samples. "
3. Dementia (Dementias)
4. Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
5. Frontotemporal Dementia (Semantic Dementia)

Related Drugs and Biologics

1. Biomarkers (Surrogate Marker)
2. Apolipoproteins E (ApoE)
3. mutalipocin II
4. Threonine (L-Threonine)
5. Interleukin-4 (Interleukin 4)
6. Ornithine Decarboxylase (Decarboxylase, Ornithine)
7. Lipids
8. Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
9. Interleukin-2 (IL2)
10. Fatty Acids (Saturated Fatty Acids)

Related Therapies and Procedures

1. Activities of Daily Living (ADL)